arrow
R

Ryotaro Nakamura

City of Hope Comprehensive Cancer Center
H指数:63
被引数:1.3万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Clinical Implications of CD19-Negative Relapse Following CD19-Directed Therapy in B-Cell Acute Lymphoblastic Leukemia
2026-08-150
PRE
Antigen-specific T cell responses to SARS-CoV-2 vaccination after Hematopoietic Cell Transplant or CAR T cell Therapy

造血细胞移植或CAR T细胞治疗后对SARS-CoV-2疫苗接种的抗原特异性T细胞反应

2026-04-070
OAAI
CHARM is Prognostic of Geriatric Morbidity and Toxicity after Allogeneic Transplant for Older Adults: BMT CTN 1704 Study

CHARM是老年患者异基因移植后预测老年病发病率和毒性的指标:BMT CTN 1704研究

2025-11-240
OAAI
Long-term survival outcomes of allo-HCT in AML with fludarabine/melphalan conditioning and tacrolimus/sirolimus GVHD prophylaxis

异基因造血干细胞移植(allo-HCT)在采用氟达拉滨/美法仑(Fludarabine/Melphalan)预处理和他克莫司/西罗莫司(Tacrolimus/Sirolimus)移植物抗宿主病(GVHD)预防方案的急性髓系白血病(AML)中的长期生存结局。

2025-11-180
OAAI
Hematopoietic Cell Transplantation, Version 3.2025

造血细胞移植,版本 3.2025

2025-10-011
PRE
Performance of treatment response assessment at day 7 by baseline acute graft-vs-host disease severity

基于基线急性移植物抗宿主病严重程度的第7天治疗反应评估表现

2025-09-250
PRE
Pulmonary manifestations during neutrophil engraftment in recipients of allogeneic hematopoietic cell transplantation for myelofibrosis

异基因造血细胞移植治疗骨髓纤维化受者中中性粒细胞植入期间的肺部表现

2025-09-240
OA
Trial of Enasidenib Maintenance Post Allogeneic Hematopoietic Cell Transplant in Patients With IDH-2 Mutated AML

在IDH-2突变急性髓系白血病异基因造血细胞移植后使用enasidenib维持治疗的试验

2025-09-190
PRE
The efficacy of targeted and immune-based therapies in adults with TP53-mutated acute lymphoblastic leukaemia

靶向治疗和免疫疗法在TP53突变急性淋巴细胞白血病患者中的疗效

2025-09-010
PRE
Refinement of Day 28 Treatment Response Criteria for Acute GVHD: A Collaboration Study of the JSTCT and MAGIC

急性GVHD第28天治疗反应标准的修订:JSTCT与MAGIC的合作研究

2025-07-030
OAAI
Out-of-Pocket Expenditures and Financial Hardship Among Patients With Myelodysplastic Syndrome Undergoing Allogeneic Transplant or Hypomethylating Agent / Supportive Care (BMT CTN 1102)

自付支出与骨髓增生异常综合征患者接受同种异体移植或低甲基化药物/支持性护理治疗时的财务困难(BMT CTN 1102)

2025-07-010
PRE
Outcomes After Melphalan-Based Reduced Intensity Allogeneic Hematopoietic Cell Transplantation in Renal Impairment

基于美法仑的减低强度异基因造血细胞移植在肾功能不全患者中的结局

2025-07-010
PRE
Novel composite health assessment risk model for older allogeneic transplant recipients: BMT-CTN 1704

新型复合健康评估风险模型用于老年异基因移植受者:BMT-CTN 1704

2025-03-200
OA
Melphalan-based conditioning with post-transplant cyclophosphamide for peripheral blood stem cell transplantation: donor effect

基于美法仑的预处理联合移植后环磷酰胺用于外周血干细胞移植:供者效应

2025-02-270
OA
Serial Clinical and Biomarker Monitoring during Graft-Versus-Host Disease Treatment Identifies Distinct Risk Strata Including an Ultra-Low Risk Group

移植物抗宿主病治疗期间的系列临床和生物标志物监测确定了不同的风险阶层,包括超低风险组

2025-01-010
PRE
A Multicenter Analysis of Allogeneic Transplant Outcomes Adults with Philadelphia-Like B-Cell Acute Lymphoblastic Leukemia in First Complete Remission
2024-12-011
PRE